Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy
- PMID: 36618947
- PMCID: PMC9811266
- DOI: 10.3389/fphar.2022.1007723
Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy
Abstract
Triplex-forming oligonucleotides (TFOs) can bind to the major groove of double-stranded DNA with high specificity and affinity and inhibit gene expression. Triplex-forming oligonucleotides have gained prominence because of their potential applications in antigene therapy. In particular, the target specificity of triplex-forming oligonucleotides combined with their ability to suppress oncogene expression has driven their development as anti-cancer agents. So far, triplex-forming oligonucleotides have not been used for clinical treatment and seem to be gradually snubbed in recent years. But triplex-forming oligonucleotides still represent an approach to down-regulate the expression of the target gene and a carrier of active substances. Therefore, in the present review, we will introduce the characteristics of triplex-forming oligonucleotides and their anti-cancer research progress. Then, we will discuss the challenges in their application.
Keywords: anti-gene technique; cancer therapy; oncogenes; triple helix formation; triplex-forming oligonucleotides (TFOs).
Copyright © 2022 Li, Zhou, Ren, Deng, Peng, Wang, Zhang and Jiang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources